Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FH535 是一种具有抗肿瘤活性的Wnt/β-catenin 和PPAR 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 287 | 现货 | ||
10 mg | ¥ 453 | 现货 | ||
25 mg | ¥ 822 | 现货 | ||
50 mg | ¥ 1,360 | 现货 | ||
100 mg | ¥ 2,180 | 现货 | ||
200 mg | ¥ 2,990 | 现货 | ||
500 mg | ¥ 4,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 497 | 现货 |
产品描述 | FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities. |
体内活性 | FH535抑制β-连环蛋白/Tcf介导的转录,同时还具有抑制共激活剂GRIP1和β-连环蛋白对PPARδ 和 PPAR的聚集作用。在表达较高的或活跃的Wnt/β-连环蛋白通路癌细胞中,FH535能够抑制细胞增殖。 |
激酶实验 | High-throughput Library Screen: Three copies of the optimized or mutated Tcf-binding element from TOPFLASH or FOPFLASH driving a secreted alkaline phosphatase reporter gene are cloned into pCEP4 plasmid, replacing the cytomegalovirus promoter. The plasmids are transfected into HepG2 cells, and hygromycin-resistant clones are pooled. Library screening is done at 20 μmol/L concentration in HepG2 serum-free media. Hits are tested in the HCT116 cell line for inhibition of TOPFLASH luciferase activity but not for inhibition of a reporter activity controlled from β-actin promoter. |
细胞实验 | Cell viability is determined by the modified 3H-thymidine incorporation assay. Briefly, cells are plated in 96-well microplates for 24 h and treated in triplicate with various concentrations of the test compound. After 48 h of compound exposure, the cells are incubated for an additional 48 h in compound-free medium. The cells are then incubated in medium containing 3H-thymidine for 24 h, washed and mixed with the scintillant in the 96-well plate. Individual wells are counted with a 96-well scintillation counter and the LC50 is calculated.(Only for Reference) |
分子量 | 361.2 |
分子式 | C13H10Cl2N2O4S |
CAS No. | 108409-83-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.1 mg/mL (75 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7685 mL | 13.8427 mL | 27.6855 mL | 69.2137 mL |
5 mM | 0.5537 mL | 2.7685 mL | 5.5371 mL | 13.8427 mL | |
10 mM | 0.2769 mL | 1.3843 mL | 2.7685 mL | 6.9214 mL | |
20 mM | 0.1384 mL | 0.6921 mL | 1.3843 mL | 3.4607 mL | |
50 mM | 0.0554 mL | 0.2769 mL | 0.5537 mL | 1.3843 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FH535 108409-83-2 Cytoskeletal Signaling DNA Damage/DNA Repair Metabolism Stem Cells Wnt/beta-catenin PPAR Beta catenin FH 535 β-catenin inhibit FH-535 Wnt Inhibitor Peroxisome proliferator-activated receptors inhibitor